clients, partners and patients to develop new treatments for NASH, diabetes and obesity.
Clinical Development and Regulatory Strategy + State-of-the-Art Clinical Facility + Full Scope CRO Services + Global Scientific Network
ProSciento Appoints Pete Nieto as Vice President of Business Development Read More »
ProSciento Presents Scientific Data at the 2nd Annual Nash Summit Read More »
View Our Presentation
Pathophysiology of Cardiovascular Disease in Diabetes Mellitus Read More »
Single Dose Euglycemic Clamp Studies Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between MK-1293 Insulin Glargine and Originator Insulin Glargine (Lantus) in Type 1 Diabetes and Healthy Subjects Read More »
FDA approves Ozempic to improve glycemic control in adults with T2D Read More »